ClinicalTrials.gg
Not yet recruitingNCT07046117TezebarrierUpdated Jul 1, 2025

Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps

An interventional study of Tezepelumab in Asthma Bronchiale and Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Medical University of Vienna. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Planned enrollment
25th of 28
20 · median 121
Started
2025
with 2 others
No phase
2 of 28
2 open now
Registered
25th of 28
by date
Lead sponsor
1 of 28
Medical University of Vienna

Among the 28 studies testing tezepelumab in Asthma, this one is the 25th largest by planned enrollment, is one of 3 that started in 2025, is one of 2 with no phase, and was the 25th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

In this study, we will investigate the effect of tezepelumab on the epithelial barrier function of the upper and lower airways in patients suffering from severe asthma with and without chronic rhinosinusitis with nasal polyps. This will be achieved by analysis of epithelial barrier function upon challenge with various harmful substances (e.g. cigarette smoke extract, allergens) in cultured primary respiratory tract epithelial cells. Furthermore we will assess changes in clinical parameters, cellular composition and inflammatory mediators.

Read the detailed description

The primary objective of the proposal is to investigate the effect of Tezepelumab on the epithelial barrier function of upper and lower airways. To that aim, epithelial cells from the upper and lower airways will be cultured to investigate the change in barrier function during Tezepelumab treatment in patients suffering from severe asthma in presence or absence of chronic rhinosinusitis with nasal polyps. In addition, mucus plugging will be quantified by computer tomography before and after Tezepelumab therapy. These data will be supplemented by cellular and mediator analyses as well as microbiome analyses. Thus, our study will unravel the molecular mechanisms and benefits underlying therapy with Tezepelumab in patients suffering from severe asthma with or without nasal polyps.

Objectives Primary objective: Effect of Tezepelumab treatment on the barrier function of upper and lower airways in patients suffering from severe asthma with and without CRSwNP. This will be achieved by analysis of epithelial barrier function upon challenge with various harmful substances (e.g. cigarette smoke extract, allergens, and rhinovirus) in cultured primary respiratory tract epithelial cells using the xCELLigence system for continuous monitoring of barrier function.

03

Conditions studied

  • Asthma Bronchiale
  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Browse trials for

Keywords

  • asthma
  • chronic rhinosinusitis with nasal polyps
  • tezepelumab
  • epithelial barrier
  • airways
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Age 18-99 years and willing to participate in the study
  3. Have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)
  4. Undergo severe asthma treatment according to GINA/DAL treatment step 4 or 5
  5. Meet the requirements for treatment of severe asthma with Tezepelumab defined as:

    • severe asthma that remains uncontrolled despite a high dosage of ICS/LABA, or that requires a high dose to prevent it from becoming uncontrolled. One of the following criteria needs to be fulfilled:

      • ACT \<20, ACQ>0.75
      • During the last 12 months 2 courses of OCS for at least 3 days due to severe asthma symptoms
      • During last 12 months one exacerbation requiring hospitalization
      • Lung function: \<80% predicted
    • FeNO ≥ 20 ppB
    • had either ≥250 eosinophils /µl measured in the blood OR measurement of blood eosinophils ≥150 cells during reduction of OCS dosing or high dose ICS and/or one measurement of sputum eosinophils > 2% or BAL eosinophils > 2%
    • Group with polyps: Presence of nasal polyps as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines
  6. mucus score of ≥ 1
  7. Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a of 3 half-lives or 3 months have passed (whichever is longer)

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with current therapy with biologics as well as therapy with biologics 12 weeks (3 half-lives) before the start of the study or history of therapy with tezepelumab 2. Pregnancy (as determined by urine pregnancy test) 3. Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity or to perform bronchoscopy 4. Patients with any other confounding underlying lung disorder including but not limited to:

    • Bronchiectasis, pulmonary fibrosis, emphysema, primary ciliary dyskinesia
    • Cystic fibrosis, any known parasitic infections and lung cancer

      5. Patients with other causes of nasal polyps than Type 2 CRS inflammation 6. Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA) allergic bronchopulmonary aspergillus and hypereosinophilic syndrome 7. for endobronchial and/or transbronchial . 8. A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study 9. Patients with comorbidity as determined by the evaluating committee 10. treatment (e.g. cyclosporine) 11. Drug and alcohol abuse 12. Current smoker and former smokers if stopped smoking \<6 months

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Asthma only

    Patients suffering from asthma in absence of CRSwNP will be administerd tezepelumab every 4 weeks

    Drug: Tezepelumab

  • Active comparator
    Asthma with CRSwNP

    Patients suffering from Asthma with CRSwNP will be administered Tezepelumab every 4 weeks

    Drug: Tezepelumab

Interventions

  • injection with Tezepelumab every 4 weeks

06

What researchers measure

Primary outcomes

  1. Change in cell index

    Changes in normalized cell index in response to barrier-damaging substances in cultured primary epithelial cells of the different disease entities using the xCELLigence system for continuous monitoring of barrier function.

    Time frame: 6 months

Secondary outcomes

  1. Change in mucus plugging

    The extent of air-trapping, bronchial wall thickening and mucus plugging per pulmonary segment will be scored independently by two thoracic radiologists.

    Time frame: 6 months

  2. Change in marker expression immune cell subsets

    Cellular composition and marker expression on cells derived from Bronchoalveolar lavage (BAL), nasal polyps and blood as assessed by a multi-colour mass cytometry panel

    Time frame: 6 months

  3. Change in inflammatory mediators

    (Inflammatory) mediator expression in BAL, lung tissue, nasal mucosa, polyp tissue (e.g. OLINK explorer)

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Scientific Data will be shared in public available databases

Supporting information: Analytic code

Time frame: from Dec 2025 with open end

Access criteria: those who are registerd with public databases or who contact the investigators via email

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jan 2028, 27 months later.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 27 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jul 1, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Aug 1, 2028
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046117
Responsible party
Marco Idzko (Univ.Prof.Dr.med., Medical University of Vienna) — Principal investigator
First posted
Jul 1, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Jul 1, 2025

Study contacts

Julia Eckl-Dorna, MD, PhD
Contact
julia.eckl-dorna@meduniwien.ac.at
+43140400 ext. 34380
Victoria Stanek
Contact
victoria.stanek@meduniwien.ac.at
Stanek ext. MSc
Marco Idzko, MD, PhD
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion